Appointment of new Director of US Operations

Cyprotex PLC

("Cyprotex" or "the Company")

Cyprotex appoint new Director of US Operations

Cyprotex PLC (AIM:CRX), a specialist Contract Research Organisation (CRO), announced today the appointment of Dr Monica Metea as Director of US Operations. The role, which commences on 26th September 2016, will provide operational and scientific leadership to the two Cyprotex facilities in the US at Watertown, MA and Kalamazoo, MI.

Prior to joining Cyprotex, Dr Metea held senior roles at WIL Research Laboratories LLC (recently acquired by Charles River Laboratories International Inc), Covance Laboratories Inc, and most recently Smithers Viscient where she held a Director's position. Dr Metea has been awarded a PhD in Neuroscience from the University of Minnesota. She is a recognised expert consultant in preclinical electrophysiology and drug safety, and has a strong background in safety pharmacology and toxicology.

Dr Anthony Baxter, Cyprotex's Chief Executive Officer, comments on the appointment: "I am delighted to welcome such an accredited scientist and leader to Cyprotex. Within the industries in which we operate, the US is the largest market. It is important therefore that we leverage this potential opportunity. We are confident that Monica has the drive, experience and credentials to direct and grow future business within this critical target market."

For further information:

Notes to Editors

About Cyprotex PLC

Cyprotex is listed on the AIM market of the London Stock Exchange (CRX). It has sites at Macclesfield and Alderley Park, both of which are near Manchester in the UK, and at Watertown, MA and Kalamazoo, MI in the US. The Company was established in 1999 and works with more than 1500 partners within the pharmaceutical and biotech industry, cosmetics and personal care industry and the chemical industry. Cyprotex acquired Apredica and the assets of Cellumen Inc. in August 2010 and the combined business provides support for a wide range of experimental and computational ADME-Tox and PK services. The acquisition of the assets and business of CeeTox in January 2014 has enabled Cyprotex to expand its range of services to target the personal care, cosmetics and chemical industries. In 2015, Cyprotex launched its new bioscience division to expand its capabilities into phenotypic and target based screening. The Company's core capabilities include high quality in vitro ADME services, mechanistic toxicology and high content toxicology screening services, including our proprietary CellCiphr® toxicity prediction technology, bioscience services, predictive modelling solutions including Cloe® PK, chemTarget, chemPK™ and chemTox, and a range of skin, ocular and endocrine disruption services. For more information, please visit www.cyprotex.com